Benzodiazepines are used frequently for premedication, induction and maintenance of general anaesthesia and for sedation in intensive care. Flumazenil, a specific benzodiazepine receptor antagonist, reverses the sedative effects of benzodiazepines by competing for benzodiazepine receptors [1] [2] [3] [4] . Common side effects include nausea and vomiting. In addition, intrinsic agonist effects have been demonstrated [2, [5] [6] [7] .
After the administration of flumazenil to antagonize midazolam-induced anaesthesia, no resedation was encountered in two reports [8, 9] . In the majority of studies, however, resedation was described [10] [11] [12] . In a clinical environment, where antagonism of the benzodiazepine effect is essential, a continuous i.v. infusion or multiple i.v. injections of flumazenil [13, 14] would be necessary to avoid resedation. As this strategy would require prolonged continuous monitoring it may be impractical. This study was performed to investigate if subcutaneous administration of flumazenil, analogous to the practice with naloxone [15, 16] , would avoid resedation.
PATIENTS AND METHODS
A randomized, double-blind design accepted by the Hospital Ethics Committee was used. Informed consent was obtained from each of 30 patients scheduled for gynaecological surgery (cervical dilatation and fractional curettage or conization) who were assigned randomly to three groups: flumazenil i.v. and placebo s. Patients with known benzodiazepine abuse, neurological disease or hepatic or renal insufficiency were excluded.
The study medication was provided in identical syringes: 8 ml for i.v. injection and 1 ml for s.c. injection.
Sedation, temporo-spatial orientation, co-operation and comprehension were evaluated on the morning before premedication (baseline) and after surgery before the injection of the study medi-cation. Additional testing was conducted 5, 30, 60, 90, 120, 150 and 180 min after injection of the study medication. The degree of sedation was rated on a scale from 0 to 4 (0 = fully awake; 1 = awake and relaxed; 2 = drowsy; 3 = asleep, but arousable; 4 = asleep, not arousable) [17] . Comprehension and co-operation were tested by requesting the patient to remove the oropharyngeal tube, raise her head or move her hands. The scaling ranged from 0 to 2 (0 = order executed on command; 1 = order executed on imitation; 2 = order not executed) [17] . Temporo-spatial orientation (0 = orientated in both modalities, 1 = orientated in one of the two modalities, 2 = totally disorientated) was determined by asking the patient about time (week, day) and location [17] .
In addition, all side effects were registered and the request for analgesics (pentazocine 15-30 mg i.v.), antiemetics (metoclopramide 5-10 mg i.v.), or both was recorded. Local tolerance to s.c. fiumazenil was assessed by visual inspection of the skin and the patients' reports of itching.
For psychometric testing, the multiple choice reaction time test (CRT) developed by Schoppe and Schuhfried was performed [18] . On the morning of the day of surgery all patients were instructed in the use of the test. The patient has to respond to the illumination of one coloured light out of five by pressing the corresponding coloured button. In addition, the patient has to differentiate between a high and a low frequency acoustic signal by depressing the appropriate button. The entire test series is composed of 50 randomized visual and acoustic signals delivered every 3 s. Patients exceeding this time limit were deemed to have taken 3 s. A record of the speed and accuracy of the responses is stored online and analysed later. The measurement variables were the choice reaction time and the number of errors.
After a training period of approximately 30 min a CRT test and errors score were recorded (baseline). The CRT was performed 5, 60, 120 and 180 min after injection of the test drug.
After initial testing, all patients received midazolam O.lmgkg" 1 and atropine 0.5 mg i.m. for premedication. A cannula was inserted into a peripheral vein and an infusion of Ringer-lactate solution was started. One hour later, on the patient's arrival in the operating room, anaesthesia was induced with fentanyl 0.1 mg and midazolam 0.15 mg kg" 1 and maintained with 66% nitrous oxide in oxygen 0.5-1.2 vol. % halothane. Assisted ventilation was performed by mask. Two patients of the control group and one patient in each treatment group received an additional 0.25 mg atropine i.v. to counteract bradycardia after induction of anaesthesia.
Halothane and nitrous oxide were discontinued after the completion of surgery and the patient was transferred to the recovery room. The duration of anaesthesia was standardized at exactly 30 min in all patients. Forty minutes after administration of midazolam (i.e. 10 min after the end of halothane inhalation) the test drug was given. Three millilitre of a solution containing either fiumazenil 0.3 mg or placebo was administered i.v. in addition to an additional single dose s.c. of 1 ml (fiumazenil 0.1 mg or placebo). One millilitre of the study medication was given i.v. every 60 s until the patient was awake or the dosage limit of a maximum of 8 ml was reached.
Haemodynamic variables were monitored throughout anaesthesia by automated oscillotonometry (Dinamap) and ECG.
The results of sedation, orientation in time and space, co-operation and comprehension are presented as median (range). Statistical differences between the groups were calculated using Wilcoxon signed rank test. Analyses within the same group were performed using the Friedman test and the Wilcoxon-Wilcox test. The physical characteristics and the results of the choice reaction time test are presented as mean (SD). Statistical differences between the groups were calculated using the Wilcoxon rank sum test. Values were considered statistically significant if P < 0.05.
RESULTS
The distribution of age, body weight, total dose of midazolam and total dose of flumazenil i.v. and s.c. of the three groups are shown in table I.
The time course of the degree of sedation is shown in figure 1 . After anaesthesia, all patients were asleep. From 5 to 30 min after injection of flumazenil (group A + group B), patients were significantly less sedated (P < 0.01). Thereafter, patients treated with flumazenil (group A + group B) became more sedated and there was no significant difference between the three groups. Patients in the control group showed a steadily improving level of sedation which was significantly different from before treatment up to 90 min (P < 0.01). Patients in group A were significantly more sedated at 180 min compared with placebo (P < 0.05). at the same time point, but did not differ from the treated group thereafter. Five minutes after the administration of either flumazenil or placebo, the group receiving active medication demonstrated a significantly shorter CRT and fewer errors compared with the control group. The difference between group B and group A was not significant at any time (table III) .
The side effects of all groups are listed in table IV. Only the frequency of nausea and vomiting was higher in the treatment groups: seven of 10 patients in group A and five of 10 in group B complained of nausea or vomiting, but none after placebo. In group A six and in group B five patients required an antiemetic.
Two patients in group B described a feeling of anxiety and two other patients cried, but did not recall unpleasant feelings when interviewed immediately after recovery. In group A one patient cried, but did not describe anxiety or distress when asked. None of these side effects occurred after injection of placebo.
The frequency of postoperative pain, headache, the need for analgesics and micturition was similar in all groups. Local toleration of the s.c. administration of flumazenil was good. Itching was not observed.
Comparison of the degree of sedation, orientation, co-operation and comprehension is shown in table II. There was no significant difference between the two treatment groups. Orientation, co-operation and comprehension values did not differ before anaesthesia. Before the administration of the study drug, patients were uncooperative and disorientated in either time or space. Five minutes after injection of flumazenil all patients (group A and group B) were co-operative and orientated. Patients receiving placebo were significantly less co-operative and less orientated DISCUSSION Our results confirm that flumazenil was effective in promptly antagonizing midazolam-induced general anaesthesia. Sedation, disorientation and co-operation-returned to near baseline values within 5 min after injection. The mean dose of flumazenil used is comparable to previous reports [8, 10, 19, 20] which ranged from 0.3 mg to 0.58 mg. These effects are well documented in the literature [8, [21] [22] [23] . The CRT test confirmed our clinical assessment of a clear difference between the treatment groups and placebo. Similar results 
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Control group (n -10) have been reported by Raeder and colleagues [24] , who used a four-choice reaction time test. The major undesirable side effects were nausea and vomiting. In previous reports the frequency of nausea and vomiting ranges from absent or rare [10, 23, 25] to 53% [8, 20] in flumazenil-treated groups. We found a higher frequency of up to 70% after flumazenil, but none after placebo. This discrepancy may be explained by the rapid awakening and the necessary movements of the body during the testing procedures. The frequency of anxiety in our patients was low and was probably related to the emotional state of the patients [23] . In contrast with Louis and colleagues [22] , who found an occurrence of 100%, the frequency of discomfort was less in our patient population who were young and unimpaired by severe medical illness. Sixty to 120 min after administration of flumazenil our patients became resedated, which is in agreement with previous reports [11, 19, 23, 26] . In some cases resedation was not seen [8, 9] and may have been a result of the short observation time or the stimulation of the testing. In our study, therefore, we allowed long resting periods between the testing cycles.
Flumazenil is cleared rapidly from the body. It has rapid hepatic metabolism (99%) and a short half-life of approximately 1 h [13, 27, 28] , whereas the half-life of midazolam is 1.5-3.5 h [29] . These pharmacokinetic differences account probably for the limited duration of the antagonism of the benzodiazepine effects and subsequent resedation.
Our attempt to eliminate resedation by additional subcutaneous administration of flumazenil was not successful. Two possibilities have to be considered to explain this observation. First, skin blood flow may be poor in the postoperative period and, second, the small dose of flumazenil 0.1 mg s.c. which we used. The sedation score after 120 min showed a tendency to be less in group B than in group A. This suggests that a higher dose of flumazenil s.c. might be effective, but would probably result in increased side effects.
It is common clinical practice to use an additional i.m. or s.c. injection of naloxone to avoid the recurrence of opioid effects [15, 16] . Our attempt to shorten recovery time using a similar strategy of subcutaneous flumazenil failed.
